Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy

  title={Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy},
  author={Mohammed Jarrar and Shalini Behl and Ganiraju C Manyam and Hany Ganah and Mohammed A. Nazir and Reem Nasab and Khaled Moustafa},
  journal={Molecular Biology Reports},
Clopidogrel and aspirin are among the most prescribed dual antiplatelet therapies to treat the acute coronary syndrome and heart attacks. However, their potential clinical impacts are a subject of intense debates. The therapeutic efficiency of clopidogrel is controlled by the actions of hepatic cytochrome P450 (CYPs) enzymes and impacted by individual genetic variations. Inter-individual polymorphisms in CYPs enzymes affect the metabolism of clopidogrel into its active metabolites and… CONTINUE READING
1 Citations
96 References
Similar Papers


Publications citing this paper.


Publications referenced by this paper.
Showing 1-10 of 96 references

experience in Singapore

  • B Chowbay, S Zhou, Lee EJ An interethnic comparison of polymorphisms of t enzymes, drug transporters
  • Drug Metab Rev 37(2):327–378 Mol Biol Rep
  • 2016

insights from the Guthrie PCI Registry

  • PCI Harjai KJ et al Six-month outcomes with or without successful
  • J Am Coll Cardiol 55(10s1):A179.E1675–A179.E1675…
  • 2016

Antiplatelet therapy in acute coronary syndromes

  • EL Grove
  • Expert Opin Pharmacother
  • 2015
1 Excerpt

Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population

  • R Priyadharsini
  • Mol Biol Rep
  • 2014
1 Excerpt

Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population

  • K Subraja
  • Eur J Clin Pharmacol
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…